120 related articles for article (PubMed ID: 30320363)
1. Affibody‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377.
Mitran B; Andersson KG; Lindström E; Garousi J; Rosestedt M; Tolmachev V; Ståhl S; Orlova A; Löfblom J
Oncol Rep; 2019 Jan; 41(1):534-542. PubMed ID: 30320363
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.
Rosestedt M; Andersson KG; Mitran B; Rinne SS; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Int J Oncol; 2017 Dec; 51(6):1765-1774. PubMed ID: 29039474
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator.
Andersson KG; Oroujeni M; Garousi J; Mitran B; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Int J Oncol; 2016 Dec; 49(6):2285-2293. PubMed ID: 27748899
[TBL] [Abstract][Full Text] [Related]
4. The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.
Garousi J; Andersson KG; Dam JH; Olsen BB; Mitran B; Orlova A; Buijs J; Ståhl S; Löfblom J; Thisgaard H; Tolmachev V
Sci Rep; 2017 Jul; 7(1):5961. PubMed ID: 28729680
[TBL] [Abstract][Full Text] [Related]
5. Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models.
Burley TA; Da Pieve C; Martins CD; Ciobota DM; Allott L; Oyen WJG; Harrington KJ; Smith G; Kramer-Marek G
J Nucl Med; 2019 Mar; 60(3):353-361. PubMed ID: 30213849
[TBL] [Abstract][Full Text] [Related]
6. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.
Garousi J; Andersson KG; Mitran B; Pichl ML; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Int J Oncol; 2016 Apr; 48(4):1325-32. PubMed ID: 26847636
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.
Mitran B; Altai M; Hofström C; Honarvar H; Sandström M; Orlova A; Tolmachev V; Gräslund T
Amino Acids; 2015 Feb; 47(2):303-15. PubMed ID: 25425114
[TBL] [Abstract][Full Text] [Related]
8. Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab.
Malmberg J; Tolmachev V; Orlova A
Int J Oncol; 2011 Apr; 38(4):1137-43. PubMed ID: 21253675
[TBL] [Abstract][Full Text] [Related]
9. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.
Tolmachev V; Rosik D; Wållberg H; Sjöberg A; Sandström M; Hansson M; Wennborg A; Orlova A
Eur J Nucl Med Mol Imaging; 2010 Mar; 37(3):613-22. PubMed ID: 19838701
[TBL] [Abstract][Full Text] [Related]
10. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.
Tolmachev V; Friedman M; Sandström M; Eriksson TL; Rosik D; Hodik M; Ståhl S; Frejd FY; Orlova A
J Nucl Med; 2009 Feb; 50(2):274-83. PubMed ID: 19164241
[TBL] [Abstract][Full Text] [Related]
11. Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules.
Sandström K; Haylock AK; Velikyan I; Spiegelberg D; Kareem H; Tolmachev V; Lundqvist H; Nestor M
Cancer Biother Radiopharm; 2011 Oct; 26(5):593-601. PubMed ID: 21834651
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer.
Li W; Ji YH; Li CX; Liu ZY; Li N; Fang L; Chang J; Tan J
World J Gastroenterol; 2016 Apr; 22(14):3758-68. PubMed ID: 27076760
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
14. Influence of composition of cysteine-containing peptide-based chelators on biodistribution of
Oroujeni M; Andersson KG; Steinhardt X; Altai M; Orlova A; Mitran B; Vorobyeva A; Garousi J; Tolmachev V; Löfblom J
Amino Acids; 2018 Aug; 50(8):981-994. PubMed ID: 29728916
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer.
Fozing T; Scheuer C; Samnick S
Eur J Med Chem; 2010 Sep; 45(9):3780-6. PubMed ID: 20538380
[TBL] [Abstract][Full Text] [Related]
16. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts.
Liu X; Dong C; Shi J; Ma T; Jin Z; Jia B; Liu Z; Shen L; Wang F
Oncotarget; 2017 Jan; 8(4):6364-6375. PubMed ID: 28031526
[TBL] [Abstract][Full Text] [Related]
18. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive quantification of target availability during therapy using paired-agent fluorescence tomography.
Meng B; Folaron MR; Strawbridge RR; Sadeghipour N; Samkoe KS; Tichauer K; Davis SC
Theranostics; 2020; 10(24):11230-11243. PubMed ID: 33042280
[TBL] [Abstract][Full Text] [Related]
20. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
